Title:
VEROTOXIN TREATMENT OF LYMPHOMAS
Document Type and Number:
WIPO Patent Application WO/2000/061183
Kind Code:
A2
Abstract:
Methods for treating lymphoma by the administration of an agent that binds Gb3 are disclosed. In one embodiment, the lymphoma may be, for example, PTLD.
Inventors:
LINGWOOD CLIFFORD A
ARBUS GERALD
ARBUS GERALD
Application Number:
PCT/CA2000/000371
Publication Date:
October 19, 2000
Filing Date:
April 07, 2000
Export Citation:
Assignee:
HSC RES DEV LP (CA)
International Classes:
A61K39/02; A61K39/108; A61K47/48; A61P35/00; C07K16/28; A61K39/00; (IPC1-7): A61K39/108; A61K39/385; A61K39/44; A61P35/00
Domestic Patent References:
| WO1998051326A1 | 1998-11-19 | |||
| WO1995022349A1 | 1995-08-24 |
Foreign References:
| EP0130132A1 | 1985-01-02 |
Other References:
MANGENEY MARIANNE ET AL: "Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen." CANCER RESEARCH, vol. 53, no. 21, 1993, pages 5314-5319, XP002030860 ISSN: 0008-5472 cited in the application
LACASSE E C ET AL: "SHIGA-LIKE TOXIN PURGES HUMAN LYMPHOMA FROM BONE MARROW OF SEVERE COMBINED IMMUNODEFICIENT MICE" BLOOD,US,W.B. SAUNDERS, PHILADELPHIA, VA, vol. 88, no. 5, 1 September 1996 (1996-09-01), pages 1561-1567, XP000673518 ISSN: 0006-4971
RANDHAWA P S ET AL: "Morphologic and immunophenotype characterization of a cell line derived from liver tissue with Epstein-Barr virus associated post-transplant lymphoproliferative disease." IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL, vol. 30A, no. 6, 1994, pages 400-406, XP000960975 ISSN: 1071-2690
ARBUS GERALD S ET AL: "Verotoxin targets lymphoma infiltrates of patients with post-transplant lymphoproliferative disease." LEUKEMIA RESEARCH, vol. 24, no. 10, October 2000 (2000-10), pages 857-864, XP000960973 ISSN: 0145-2126
LACASSE E C ET AL: "SHIGA-LIKE TOXIN PURGES HUMAN LYMPHOMA FROM BONE MARROW OF SEVERE COMBINED IMMUNODEFICIENT MICE" BLOOD,US,W.B. SAUNDERS, PHILADELPHIA, VA, vol. 88, no. 5, 1 September 1996 (1996-09-01), pages 1561-1567, XP000673518 ISSN: 0006-4971
RANDHAWA P S ET AL: "Morphologic and immunophenotype characterization of a cell line derived from liver tissue with Epstein-Barr virus associated post-transplant lymphoproliferative disease." IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL, vol. 30A, no. 6, 1994, pages 400-406, XP000960975 ISSN: 1071-2690
ARBUS GERALD S ET AL: "Verotoxin targets lymphoma infiltrates of patients with post-transplant lymphoproliferative disease." LEUKEMIA RESEARCH, vol. 24, no. 10, October 2000 (2000-10), pages 857-864, XP000960973 ISSN: 0145-2126
Attorney, Agent or Firm:
Fritz, Joachim T. (Ontario K1P 5Y7, CA)
Download PDF:
Claims:
CLAIMS What is claimed is:
| 1. | A method for inducing lymphoma cell death, the method comprising administering an effective amount of an agent that binds Gb3, such that lymphoma cell death occurs. |
| 2. | The method of claim 1, wherein the lymphoma cell is a lymphoma cell of B cell origin. |
| 3. | The method of claim 2, wherein the lymphoma cell of B cell origin is EBV positive. |
| 4. | The method of claim 1, wherein the agent is a verotoxin. |
| 5. | The method of claim 4, wherein the verotoxin is selected from the group consisting of verotoxin 1, verotoxin 1 Bsubunit, verotoxin 2, and verotoxin 2c. |
| 6. | A method for treating a disorder characterized by infiltrating lymphoma cells, the method comprising administering to a subject in need thereof an effective amount of an agent capable of binding Gb3 and inducing the death of the lymphoma cells such that the disorder is treated. |
| 7. | The method of claim 6, wherein the disorder is lymphoma. |
| 8. | The method of claim 7, wherein said lymphoma is a cutaneous T cell lymphoma. |
| 9. | The method of claim 8, wherein said lymphoma is selected from the group consisting of Mycosis Fungoides, sezary syndrome, related cutaneous disease lymphomatoid papilosis, and PTLD. |
| 10. | The method of claim 9, wherein said lymphoma is PTLD. |
| 11. | The method of claim 10, wherein said PTLD is associated with renal, heart, lung or liver transplantation. |
| 12. | The method of claim 6, wherein the agent is a verotoxin. |
| 13. | The method of claim 12, wherein the verotoxin is selected from the group consisting of verotoxin 1, verotoxin 1 Bsubunit, verotoxin 2, and verotoxin 2c. |
| 14. | The method of claim 6, wherein the agent is administered in a pharmaceutically acceptable carrier. |
| 15. | The method of claim 6, wherein the agent is selected from the group consisting of Pag adhesin linked to a toxin and an antibody to Gb3 linked to a toxin. |
| 16. | The method of claim 15, wherein the toxin is ricin or a ricin derivative. |
| 17. | The method of claim 6, wherein the subject is human. |
| 18. | The method of claim 17, wherein said human is HIV positive. |
| 19. | A kit comprising an agent capable of binding Gb3, such that lymphoma cell death occurs, a container, and instructions for administering said agent such that lymphoma cell death occurs. |
| 20. | The kit of claim 19 wherein said agent is a verotoxin. |
| 21. | A method of treating PTLD in a human comprising administering an effective amount of a verotoxin, such that PTLD is treated. |
| 22. | The method of claim 21, wherein said human is a liver transplant recipient. |
| 23. | The method of claim 21, wherein said human is a renal transplant recipient. |
| 24. | The method of claim 21, wherein said human is a heart transplant recipient. |
| 25. | The method of claim 21, wherein said human is a lung transplant recipient. |
Description:
INTERNATIONALSEARCHREPORT| Intel analApplicationNo PCT/CA00/00371 C.(Continuation)DOCUMENTSCONSIDEREDTOBERELEVANT Category° Citation ofdocument,withindication,whereappropriate,oftherelevantpass
agesRelevanttoclaimNo. XLACASSEECETAL:"SHIGA-LIKETOXIN1-5, PURGESHUMANLYMPHOMAFROMBONEMARROWOF19-25 SEVERECOMBINEDIMMUNODEFICIENTMICE" BLOOD,US,W.B.SAUNDERS,PHILADELPHIA,VA, vol.88,no.5, 1September1996(1996-09-01),pages 1561-1567,XP000673518 ISSN:0006-4971 thewholedocument ARANDHAWAPSETAL:"Morphologicand3,9-11, immunophenotypecharacterizationofacell21,22 linederivedfromlivertissuewith Epstein-Barrvirusassociated post-transplantlymphoproliferative disease." INVITROCELLULAR&DEVELOPMENTALBIOLOGY ANIMAL, vol.30A,no.6,1994,pages400-406, XP000960975 ISSN:1071-2690 abstract AWO9851326A(HSCRESEARCHAND1-25 DEVELOPMENTLIMITEDPARTNERSHIP) 19November1998(1998-11-19) claims1-20 AWO9522349A(GEVAR)1-25 24August1995(1995-08-24) claims1-10 TARBUSGERALDSETAL:"Verotoxintargets1-25 lymphomainfiltratesofpatientswith post-transplantlymphoproliferative disease." LEUKEMIARESEARCH, vol.24,no.10,October2000(2000-10), pages857-864,XP000960973 ISSN:0145-2126 abstract 1 INTERNATIONALSEARCHREPORT Me.onal ApplicationNo mtormation on patenttamily members PCT/CA 00/00371 PatentdocumentPublicationPatentfamily Publication citedinsearchreportdatemember(s)date EP0130132A02-01-1985FR2547731A28-12-1984 JP60069034A19-04-1985 WO9851326A19-11-1998AU7348998A08-12-1998 WO9522349A24-08-1995CA2116179A23-08-1995 AT193451T15-06-2000 AU701100B21-01-1999 AU1703195A04-09-1995 DE69517302D06-07-2000 EP0746337A11-12-1996 JP10500103T06-01-1998 US5968894A19-10-1999